

APPENDIX 15

Self-Evaluation - Review

1. What is the epidemiological data for dengue? ([Section 1, P1](#))

2. How to diagnose dengue? ([Section 3.7, P20, Appendix 5](#))

a. Clinical

- i. Latest definition of DF, DHF, DSS ([Section 3.1, P6](#))
- ii. Stages of disease and pitfalls of WHO Classification ([Section 3.5, P16](#))
- iii. Differential diagnosis ([Section 3.7, P20](#))
- iv. Unusual presentation (hepatitis, liver failure, acute abdomen, encephalitis, myocarditis) ([Section 3.6, P19](#))
- v. Co-infection – Typhoid, septicemia, malaria ([Section 3.7, P20](#))

b. Laboratory diagnosis and its pitfalls ([Section 5, P 24, Appendix 5](#))

- i. When should IgM and IgG be taken? Role of rapid test kit. ([Section 5.2.1, P25](#))
- ii. What is the role of PCR / NS1 in the diagnosis? ([Section 5.2.2, P27](#))

3. How to manage the patients with dengue infection as outpatients and in the emergency facility? ([Appendix 3a – Form O](#))

- i. OPD and A/E triaging-fast tracking during outbreak ([Section 7.2, P34](#))
- ii. Who can be treated at home? Clinical and laboratory criteria – risk stratification at first contact ([Table 6, P33](#))
- iii. When should the GP refer the suspected dengue case to OPD or hospital? ([Section 7.3.1, P34](#))
- iv. What should be the home care advice ([Appendix 3a, Form O](#))
- v. Specific out patient management and follow-up ([Appendix 3a, Form O](#))

4. When to hospitalize?

- i. Clinical and laboratory criteria including social assessment ([Section 7.3.1, P34](#))
- ii. Co-morbidities (which need hospital admission)? ([Section 7.3.1, P34](#))
- iii. Communication and notification protocol (government / inter-departmental/ inter-hospital and inter healthcare facilities) ([Appendix 4a, 4b, 4c](#))
- iv. Role of bed netting and/or mosquito repellent in the hospital setting-place under general issues ([Section 9, P55](#))

5. How to monitor the patient in the ward?

- i. What to monitor - parameter ([Table 8, P 38, Appendix 2a, 2b, 2c, 3b](#))
- ii. Pitfalls of management ([Section 7.5.1, P39](#))
- iii. Alarm triggers - Aid chart /alert card /refer algorithm ([Table 5, P33](#))

6. When to refer patient from district hospital without specialist to general hospital? ([Section 7.3.2, P35](#))

- i. Clinical and laboratory criteria
- ii. Risk stratification protocol,
- iii. When to obtain early specialist advice for those at higher risk

7. When to refer the patient for high dependency management? How to manage the critically ill dengue patient?

- i. What are the clinical criteria for referral to HDU. ([Section 7.7 P50](#))
- ii. Criteria for respiratory and hemodynamic support. ([Section 7.7.1, 7.7.2, P 50, 51](#))
- iii. Guide on safety and risk of invasive procedures ([Section 7.7.3, P52](#))

8. What should be the fluid management in DF/ DHF /DSS? ([Section 7.5, P39, Algorithms A & B, P 45, 46](#))

9. DHF/DSS

- i. Definition based on WHO classification ([Section 3.5, P16](#))
- ii. Clinical features- compensated & decompensated ([Algorithms A & B, P 45, 46](#))
- iii. Management of shock ([Algorithms A & B, P 45, 46](#))

10. How do we manage hematological and hemostatic abnormalities?

- i. Interpreting laboratory results (particularly HCT) ([Section 5.1, P24](#))
- ii. Is there a role of prophylactic transfusion? ([Section 7.6.5, P 49](#))
- iii. Is there any role of prophylactic platelet transfusion? ([Section 7.6.5, P49](#))

11. How to management bleeding in dengue patient?

- i. What is considered to be significant bleeding? ([Section 7.6.2, P 47](#))
- ii. GIT Bleed - role of OGDS/ PPI and other treatment ([Section 7.6.4, P48](#))
- iii. Use of blood and blood products ([Section 7.5.4, P 42](#) , [Algorithms A & B, P 45, 46](#))
- iv. Role of vitamin K and Tranexamic acid ([Section 7.6.6, P49](#))
- v. Recognizing occult bleed ([Section 7.6.2, P47](#))

12. Is there a role of drug therapy in DHF/DSS?

- i. Role of recombinant Factor VII ([Section 7.6.6, P49](#))
- ii. Role of IV- Immunoglobulin G ([Section 7.6.6, P49](#))
- iii. Role of steroid ([Section 7.6.6, P49](#))

13. What are the discharge criteria? ([Section 8, P 54](#))**14. What is the guidance for follow-up for those patients where**

- i. Dengue serology returns negative ([Section 5.2.1, P25](#))
- ii. Complications develop (patients with complications should remain admitted...common sense!!)